MX366955B - Crlx101 para usarse en el tratamiento de cáncer. - Google Patents
Crlx101 para usarse en el tratamiento de cáncer.Info
- Publication number
- MX366955B MX366955B MX2016013249A MX2016013249A MX366955B MX 366955 B MX366955 B MX 366955B MX 2016013249 A MX2016013249 A MX 2016013249A MX 2016013249 A MX2016013249 A MX 2016013249A MX 366955 B MX366955 B MX 366955B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- cdp
- camptothecin
- crlx101
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960005529 CRLX101 Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24275209P | 2009-09-15 | 2009-09-15 | |
| US31703910P | 2010-03-24 | 2010-03-24 | |
| US33215010P | 2010-05-06 | 2010-05-06 | |
| US38185110P | 2010-09-10 | 2010-09-10 | |
| PCT/US2010/048973 WO2011034954A1 (en) | 2009-09-15 | 2010-09-15 | Treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX366955B true MX366955B (es) | 2019-07-31 |
Family
ID=43758997
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013249A MX366955B (es) | 2009-09-15 | 2010-09-15 | Crlx101 para usarse en el tratamiento de cáncer. |
| MX2012003046A MX342709B (es) | 2009-09-15 | 2010-09-15 | Tratamiento contra el cancer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012003046A MX342709B (es) | 2009-09-15 | 2010-09-15 | Tratamiento contra el cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20110160159A1 (enExample) |
| EP (1) | EP2477985B1 (enExample) |
| JP (6) | JP5855568B2 (enExample) |
| CN (1) | CN102666533A (enExample) |
| AU (1) | AU2010295646B2 (enExample) |
| BR (1) | BR112012005594A2 (enExample) |
| CA (2) | CA2774015A1 (enExample) |
| EA (1) | EA201200486A1 (enExample) |
| IL (1) | IL218575A0 (enExample) |
| MX (2) | MX366955B (enExample) |
| WO (1) | WO2011034954A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| CN104383554B (zh) | 2002-09-06 | 2018-06-08 | 天蓝制药公司 | 用于传递治疗剂的以环糊精为基础的聚合物 |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| MX336339B (es) | 2009-10-29 | 2016-01-14 | Aventis Pharma Sa | Nuevo uso antitumoral de cabazitaxel. |
| US20120064107A1 (en) * | 2010-05-18 | 2012-03-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other disease |
| US20130196906A1 (en) * | 2012-01-31 | 2013-08-01 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| HK1214128A1 (zh) * | 2012-10-05 | 2016-07-22 | Bluelink Pharmaceuticals, Inc. | 癌症的治療 |
| US20240139324A1 (en) | 2012-12-13 | 2024-05-02 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
| ES2819573T3 (es) | 2012-12-13 | 2021-04-16 | Immunomedics Inc | Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A |
| US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| EP2900277B1 (en) | 2012-12-13 | 2022-02-16 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| US12310958B2 (en) | 2012-12-13 | 2025-05-27 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US9714266B2 (en) | 2013-02-21 | 2017-07-25 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3) |
| EP2801370A1 (en) * | 2013-05-07 | 2014-11-12 | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron | Methods and compositions for the treatment of cancer |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| WO2015048467A1 (en) * | 2013-09-27 | 2015-04-02 | Cerulean Pharma Inc. | Treatment of cancer |
| EP3096752A4 (en) * | 2014-01-24 | 2017-10-18 | Sirtex Medical Limited | Treatment of neoplasia |
| US20180028531A1 (en) * | 2015-02-12 | 2018-02-01 | BeyondSpring Phamaceuticals, Inc. | Use of plinabulin in combination with immune checkpoint inhibitors |
| US10238650B2 (en) | 2015-03-06 | 2019-03-26 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a RAS mutation |
| JP6746845B2 (ja) | 2015-04-22 | 2020-08-26 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| ES2910035T3 (es) | 2015-07-13 | 2022-05-11 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina |
| WO2017031442A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| FR3040860B1 (fr) * | 2015-09-10 | 2020-05-15 | Universite de Bordeaux | Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique |
| JP2018536655A (ja) * | 2015-11-03 | 2018-12-13 | ナノプロティアジェン， リミテッド | ポリマーナノ粒子 |
| BR112018016054A2 (pt) | 2016-02-08 | 2019-02-12 | Beyondspring Pharmaceuticals, Inc. | composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo |
| CA3011372A1 (en) | 2016-02-10 | 2017-08-17 | Immunomedics, Inc. | Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers |
| WO2017177055A1 (en) * | 2016-04-08 | 2017-10-12 | Liang Zhao | Cyclodextrin-based polymers for therapeutic delivery |
| CA3016917A1 (en) | 2016-04-27 | 2017-11-02 | Immunomedics, Inc. | Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| MX389200B (es) | 2016-06-06 | 2025-03-20 | Beyondspring Pharmaceuticals Inc | Composición y método para reducir la neutropenia. |
| WO2018102769A1 (en) * | 2016-12-01 | 2018-06-07 | Bluelink Pharmaceuticals, Inc. | Treatment of cancer |
| CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
| KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| US10918734B2 (en) | 2017-03-27 | 2021-02-16 | Immunomedics, Inc. | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| MX420412B (es) * | 2018-06-01 | 2025-02-10 | Beyondspring Pharmaceuticals Inc | Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr. |
| EP3866812A1 (en) | 2018-10-17 | 2021-08-25 | BioLineRx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| WO2020148744A1 (en) | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| US20220072087A1 (en) | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2021119464A1 (en) * | 2019-12-13 | 2021-06-17 | Veri Nano Inc. | Compositions and modular nano- and microparticles for the delivery of various agents and use thereof |
| EP4093439A1 (en) * | 2020-01-22 | 2022-11-30 | MedImmune Limited | Compounds and conjugates thereof |
| WO2022150561A1 (en) * | 2021-01-08 | 2022-07-14 | Starton Therapeutics, Inc. | Stable solutions of immunomodulatory imide compounds for parenteral use |
| CN114904013A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 硫酸乙酰肝素-骨化三醇偶联物，包含其的乙酰肝素酶响应性纳米粒，其制备方法及用途 |
| CN115109258A (zh) * | 2021-03-19 | 2022-09-27 | 江西中医药大学 | 7-乙基-10-羟基喜树碱聚合物、制备方法及其应用 |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
| US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| ES2058081T3 (es) | 1986-09-05 | 1994-11-01 | American Cyanamid Co | Poliesteres que contienen bloques de oxido de alquileno como sistemas de administracion de medicamentos. |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| FR2665169A1 (fr) | 1990-07-30 | 1992-01-31 | Rhone Poulenc Chimie | Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres. |
| US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| AU756796B2 (en) * | 1998-10-16 | 2003-01-23 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Combination therapy with VIP antagonist |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| AUPP913999A0 (en) * | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| US6420378B1 (en) * | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| AU2003243561A1 (en) * | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| CN104383554B (zh) | 2002-09-06 | 2018-06-08 | 天蓝制药公司 | 用于传递治疗剂的以环糊精为基础的聚合物 |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| AU2003299651A1 (en) * | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7358262B2 (en) * | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
| CN1216057C (zh) * | 2003-03-28 | 2005-08-24 | 贵州省生物研究所 | 喜树碱类似物的衍生物及其制备方法 |
| WO2006004574A2 (en) * | 2004-02-19 | 2006-01-12 | Abbott Laboratories | Method for using gamma cyclodextrin to control blood glucose and insulin secretion |
| ES2564127T5 (es) * | 2004-06-04 | 2020-03-26 | Genentech Inc | Mutaciones en EGFR |
| TW200640493A (en) * | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
| US20090202989A1 (en) * | 2005-06-28 | 2009-08-13 | Hillan Kenneth J | Egfr and kras mutations |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| KR100917809B1 (ko) * | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008148080A2 (en) * | 2007-05-24 | 2008-12-04 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin] |
| US20100056555A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
| JP2012522055A (ja) * | 2009-03-30 | 2012-09-20 | セルリアン・ファーマ・インコーポレイテッド | ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法 |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
-
2010
- 2010-09-15 EP EP10817784.1A patent/EP2477985B1/en active Active
- 2010-09-15 MX MX2016013249A patent/MX366955B/es unknown
- 2010-09-15 EA EA201200486A patent/EA201200486A1/ru unknown
- 2010-09-15 BR BR112012005594A patent/BR112012005594A2/pt not_active Application Discontinuation
- 2010-09-15 CA CA2774015A patent/CA2774015A1/en not_active Abandoned
- 2010-09-15 AU AU2010295646A patent/AU2010295646B2/en not_active Ceased
- 2010-09-15 WO PCT/US2010/048973 patent/WO2011034954A1/en not_active Ceased
- 2010-09-15 US US12/883,084 patent/US20110160159A1/en not_active Abandoned
- 2010-09-15 JP JP2012529881A patent/JP5855568B2/ja not_active Expired - Fee Related
- 2010-09-15 CN CN2010800410580A patent/CN102666533A/zh active Pending
- 2010-09-15 MX MX2012003046A patent/MX342709B/es active IP Right Grant
- 2010-09-15 CA CA2939165A patent/CA2939165A1/en not_active Abandoned
-
2012
- 2012-03-11 IL IL218575A patent/IL218575A0/en unknown
-
2013
- 2013-01-10 US US13/738,630 patent/US20130338103A1/en not_active Abandoned
- 2013-02-15 US US13/769,046 patent/US20130164282A1/en not_active Abandoned
-
2014
- 2014-11-04 JP JP2014223985A patent/JP2015025020A/ja not_active Withdrawn
-
2015
- 2015-04-01 US US14/675,815 patent/US20160058875A1/en not_active Abandoned
-
2016
- 2016-03-09 JP JP2016045695A patent/JP2016106143A/ja active Pending
-
2017
- 2017-04-26 US US15/498,056 patent/US20180071404A1/en not_active Abandoned
- 2017-10-10 JP JP2017196769A patent/JP2017226708A/ja not_active Withdrawn
-
2020
- 2020-06-25 JP JP2020109574A patent/JP2020164547A/ja active Pending
-
2022
- 2022-08-29 JP JP2022135758A patent/JP2022166327A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20180071404A1 (en) | 2018-03-15 |
| JP2022166327A (ja) | 2022-11-01 |
| EP2477985A4 (en) | 2013-05-15 |
| JP2016106143A (ja) | 2016-06-16 |
| AU2010295646A1 (en) | 2012-04-05 |
| EP2477985B1 (en) | 2018-11-07 |
| US20160058875A1 (en) | 2016-03-03 |
| BR112012005594A2 (pt) | 2015-09-08 |
| US20110160159A1 (en) | 2011-06-30 |
| WO2011034954A1 (en) | 2011-03-24 |
| MX342709B (es) | 2016-10-10 |
| MX2012003046A (es) | 2012-09-07 |
| JP2015025020A (ja) | 2015-02-05 |
| CN102666533A (zh) | 2012-09-12 |
| CA2939165A1 (en) | 2011-03-24 |
| EP2477985A1 (en) | 2012-07-25 |
| CA2774015A1 (en) | 2011-03-24 |
| EA201200486A1 (ru) | 2012-08-30 |
| JP2013504630A (ja) | 2013-02-07 |
| US20130338103A1 (en) | 2013-12-19 |
| JP2017226708A (ja) | 2017-12-28 |
| AU2010295646B2 (en) | 2016-02-11 |
| US20130164282A1 (en) | 2013-06-27 |
| IL218575A0 (en) | 2012-05-31 |
| JP2020164547A (ja) | 2020-10-08 |
| JP5855568B2 (ja) | 2016-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX342709B (es) | Tratamiento contra el cancer. | |
| HK1214128A1 (zh) | 癌症的治療 | |
| MY185666A (en) | Anticancer pyridopyrazines via the inhibition of fgfr kinases | |
| PH12014501229A1 (en) | Antibody-drug conjugates and related compounds, compositions, and methods | |
| WO2010111406A3 (en) | Purine derivatives useful as anti - cancer agents | |
| MX344786B (es) | Composiciones y metodos para tratar enfermedad de gaucher. | |
| UA115983C2 (uk) | Інгібітори днк-пк | |
| SG10201407927UA (en) | Imidazopyridine derivatives as jak inhibitors | |
| MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
| NZ597517A (en) | 5-fluoropyrimidinone derivatives | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| GEP201706688B (en) | Cdk8/cdk19 selective inhibitors and their use in anti- metastatic and chemopreventative methods for cancer | |
| IN2012DN00971A (enExample) | ||
| WO2010150211A3 (en) | Use of derivatives of indoles for the treatment of cancer | |
| IN2012DN03182A (enExample) | ||
| MX2011003738A (es) | Conjugados hpma-docetaxel o gemcitabine y sus usos asociados. | |
| MX2011008195A (es) | Derivados de indol como agentes anticancer. | |
| MX2011011431A (es) | Composicion para el tratamiento de cancer de prostata. | |
| WO2011020107A3 (en) | Compositions and methods for detection and treatment of breast cancer | |
| NZ597570A (en) | N1-acyl-5-fluoropyrimidinone derivatives | |
| MX2012010448A (es) | Conjugados de carbohidrato-poli aminoacido-farmaco. | |
| IN2012DN03404A (enExample) | ||
| WO2012162513A3 (en) | Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors | |
| MX2009008249A (es) | Composicion farmaceutica que comprende derivado de camptotecina. | |
| MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. |